Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H2 2019
Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H2 2019
SUMMARY
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene. It activates several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. It mediates the phosphorylation of PTPN11, an activator of this pathway. It phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. It mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology.
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 3 and 2 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Genetic Disorders which include indications Non-Small Cell Lung Cancer, Anaplastic Large Cell Lymphoma (ALCL), Neuroblastoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Non-Hodgkin Lymphoma, Breast Cancer, Central Nervous System (CNS) Tumor, Gallbladder Cancer, Head And Neck Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Thyroid Cancer, Angiosarcoma, Astrocytoma, Brain Cancer, Clear Cell Squamous Cell Carcinoma, Esophageal Cancer, Fibrosarcoma, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Sensitive Breast Cancer, Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Liver Cancer, Lymphoma, Malignant Neoplasms, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Carcinoma, Osteolytic Bone Metastasis, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma, Synovial Sarcoma, Triple-Negative Breast Cancer (TNBC), Uterine Cancer and Uveal Melanoma.
The latest report Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H2 2019, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene. It activates several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. It mediates the phosphorylation of PTPN11, an activator of this pathway. It phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. It mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology.
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 3 and 2 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Genetic Disorders which include indications Non-Small Cell Lung Cancer, Anaplastic Large Cell Lymphoma (ALCL), Neuroblastoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Non-Hodgkin Lymphoma, Breast Cancer, Central Nervous System (CNS) Tumor, Gallbladder Cancer, Head And Neck Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Thyroid Cancer, Angiosarcoma, Astrocytoma, Brain Cancer, Clear Cell Squamous Cell Carcinoma, Esophageal Cancer, Fibrosarcoma, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Sensitive Breast Cancer, Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Liver Cancer, Lymphoma, Malignant Neoplasms, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Carcinoma, Osteolytic Bone Metastasis, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma, Synovial Sarcoma, Triple-Negative Breast Cancer (TNBC), Uterine Cancer and Uveal Melanoma.
The latest report Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H2 2019, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)
- The report reviews Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Overview
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AnHeart Therapeutics Inc
Ascentage Pharma Group International
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Turning Point Therapeutics Inc
Xcovery Holding Company LLC
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Drug Profiles
APG-2449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ensartinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lorlatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
repotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WY-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Dec 13, 2019: Lancet Oncology: Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases
Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of Repotrectinib in pediatric patients
Nov 08, 2019: Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer
Oct 30, 2019: European Society for Medical Oncology: Phase I/II study results with Lorlatinib in ROS1-positive advanced NSCLC
Oct 29, 2019: Vanderbilt Oncologists publish results of first study to demonstrate clinical utility of resolution liquid biopsy assay to monitor response and resistance to Ensartinib
Oct 17, 2019: The Lancet Respiratory Medicine published study shows Ensartinib holds promise as a new treatment option for ALK-positive Non-Small Cell Lung Cancer (NSCLC)
Sep 25, 2019: Preclincal results of Baoyuan's next-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications
Sep 06, 2019: Chugai files for expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive NSCLC
Sep 04, 2019: Chugai launches Rozlytrek, an Anticancer Agent for the treatment of NTRK Fusion-Positive Solid Tumors
Sep 03, 2019: Turning Point Therapeutics announces updated interim clinical data of Repotrectinib
Aug 21, 2019: ROZLYTREK (entrectinib), FDA approved for hard-to-treat NTRK fusion-positive tumors, available at Biologics by McKesson
Aug 16, 2019: FDA approves Roche Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
Aug 15, 2019: FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
Jun 27, 2019: Chugai obtains Approval of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for Rozlytrek
Jun 19, 2019: Japan first to approve Roche’s tumour-agnostic medicine Rozlytrek
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Overview
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AnHeart Therapeutics Inc
Ascentage Pharma Group International
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Turning Point Therapeutics Inc
Xcovery Holding Company LLC
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Drug Profiles
APG-2449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ensartinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lorlatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
repotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WY-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Dec 13, 2019: Lancet Oncology: Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases
Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of Repotrectinib in pediatric patients
Nov 08, 2019: Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer
Oct 30, 2019: European Society for Medical Oncology: Phase I/II study results with Lorlatinib in ROS1-positive advanced NSCLC
Oct 29, 2019: Vanderbilt Oncologists publish results of first study to demonstrate clinical utility of resolution liquid biopsy assay to monitor response and resistance to Ensartinib
Oct 17, 2019: The Lancet Respiratory Medicine published study shows Ensartinib holds promise as a new treatment option for ALK-positive Non-Small Cell Lung Cancer (NSCLC)
Sep 25, 2019: Preclincal results of Baoyuan's next-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications
Sep 06, 2019: Chugai files for expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive NSCLC
Sep 04, 2019: Chugai launches Rozlytrek, an Anticancer Agent for the treatment of NTRK Fusion-Positive Solid Tumors
Sep 03, 2019: Turning Point Therapeutics announces updated interim clinical data of Repotrectinib
Aug 21, 2019: ROZLYTREK (entrectinib), FDA approved for hard-to-treat NTRK fusion-positive tumors, available at Biologics by McKesson
Aug 16, 2019: FDA approves Roche Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
Aug 15, 2019: FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
Jun 27, 2019: Chugai obtains Approval of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for Rozlytrek
Jun 19, 2019: Japan first to approve Roche’s tumour-agnostic medicine Rozlytrek
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AnHeart Therapeutics Inc, H2 2019
Pipeline by Ascentage Pharma Group International, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Turning Point Therapeutics Inc, H2 2019
Pipeline by Xcovery Holding Company LLC, H2 2019
Dormant Projects, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AnHeart Therapeutics Inc, H2 2019
Pipeline by Ascentage Pharma Group International, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Turning Point Therapeutics Inc, H2 2019
Pipeline by Xcovery Holding Company LLC, H2 2019
Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
AnHeart Therapeutics Inc
Ascentage Pharma Group International
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Turning Point Therapeutics Inc
Xcovery Holding Company LLC
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
AnHeart Therapeutics Inc
Ascentage Pharma Group International
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Turning Point Therapeutics Inc
Xcovery Holding Company LLC
